

# The Use of AFP-Complexes to Induce Apoptosis in Cancer Cells

V. Pak\*

Constab Pharmaceutical Inc., MaRS Centre, Toronto, Canada

**Abstract:** An anticancer “magic bullet” should have both efficacy and specificity parts. We have used an effective Apoptosis Inducer to trigger the apoptosis. Alpha-fetoprotein was used to deliver Apoptosis Inducers specifically to cancer cells. The AFP-AI complex inhibited tumor growth in mice, enlarged mice life survival and has shown a 50% response in patients with metastatic colorectal cancer.

**Keywords:** Cancer, apoptosis inducer, targeted delivery, alpha-fetoprotein, multi drug resistance.

## INTRODUCTION

Cancer is the proliferation/apoptosis overbalance. Proliferation and apoptosis are different systems and are used completely differently like the car gas and brake systems (Fig. 1). Traditional anticancer drugs mainly aim at suppressing proliferation by any mean (more than 700 molecular targeted agents are currently in trials), but directly activating apoptosis is a better idea (less than 30 agents in trials) [1, 2]. Apoptosis is responsible for recycling billions of cells everyday in the body. Cancer cells accumulate mutations in both proliferation and apoptosis systems, but crucial mutations in the apoptosis system help them to avoid the natural suicidal pathway. To overcome the broken apoptosis elements, the drug should act “downstream” of mutated apoptosis cascade elements (Fig. 1). To trigger the apoptosis, a drug needs to: 1. be specific to cancer cell, 2. provide direct Apoptosis Inducer (AI) internalization, 3. Use AI acting “downstream” of the broken apoptosis cascade element. For those purposes, several combinations can be obtained with nanoparticles, immunoliposomes, cell-penetrating peptides, small molecule AIs, etc. We have prepared a non-covalent complex of alpha-fetoprotein (AFP) that can specifically deliver AI to cancer cells and act on functional executive apoptosis elements.

## EFFECTIVE KILLING: DON'T REINVENT THE WHEEL – FIX THE BRAKES

Many cancer drugs are not optimal and often ineffective since they aim at the targets within the proliferation system (for example, DNA) which might not lead to the cancer cell death due to a frequent mutation of the p53 protein or other mutations in apoptosis pathways (Fig. 1) [3].

The problem of specific and effective elimination of definite cells in the body is already solved in Nature. Cytotoxic T lymphocytes (CTL), for example, use this mechanism. They first recognize wrong cell by membrane antigens and then use perforin for the internalization of granzyme B that activates caspases – the final enzymes within the apoptosis cascade (Fig. 1) [4]. Granzyme B is a direct apoptosis inducer and is not dependent on “upstream” cancer cell mutations such as p53 and others. For this reason, CTL can

“fix the brakes” meaning they are using undamaged apoptosis elements inside cancer cells (Fig. 1). Traditional chemotherapy targeting proliferation system elements (for example, doxorubicin: DNA) can be attributed to indirect apoptosis inducers because it can lead to the following next activation of a apoptosis. Non-repairable DNA mutations caused by doxorubicin lead to p53-dependant apoptosis in normal cells. Direct apoptosis inducers on the opposite, trigger apoptosis themselves. The closer direct apoptosis inducer can act on a late apoptosis event less chances are that cancer cell mutations might prevent its action. The ideal situation is that caspase activators such as the P-AC-1 molecule, being the last target in the cascade, will activate procaspase 3 thus triggering caspase 3 actions and demonstrate an effective anticancer action [5].

We tried to copy the effective natural CTL “know-how” to find and kill cancer cells by combining our lessons learned from CTL and using the known biological tools.


A membrane is considered being the edge between life and death. Damage in the membrane of mitochondria, endoplasmic reticulum, lysosome or peroxisome can lead to the whole eukaryotic cell death. The membrane of mitochondria was chosen as a target because mitochondrion is a “point of no return” in the intrinsic apoptosis pathway [6]. We have used proven apoptosis inducers acting on mitochondrion such as atractyloside, betulinic acid [7, 8] and an endoplasmic reticulum apoptosis inducer thapsigargin [9]. Within the intrinsic apoptosis pathway, the mitochondrion acts downstream of the p53 protein. P53 is inactive in more than 50% of cancer cells and often leads to multi drug resistance (MDR) [10]. Atractyloside was shown to induce apoptosis in p53-unfunctional HuH-7 cancer cells [11].

Since many of the agents do not cross the plasma membrane, we had to use agents combined to a special delivery system in order to induce their internalization of those agents with a special delivery system. Moreover, this delivery system should have the ability to select cancer cells and avoid healthy tissues.

## SPECIFIC DELIVERY

AFP may be responsible for embryotoxic and teratogenic action of some drugs, pollutants and chemicals. One of the

\*Address correspondence to this author at the Constab Pharmaceutical Inc., MaRS Centre, Toronto, Canada; E-mail: vpak@constabpharma.com



**Fig. (1).** Proliferation and apoptosis systems and associated anticancer drug targets. Illustration (c) 2008 AXS Biomedical Animation Studio. Used with permission.

explanations of this phenomenon is that AFP has the ability to take toxins from mother's blood and bring it to the embryo [12]. In such case, AFP should compete with the mother's albumin for binding to the toxin. Among many other substrates AFP has the strongest binding affinity to polyunsaturated fatty acids (PUFA). After the AFP-PUFA complex endocytosis by embryo cells the PUFA is internalized [13]. We have substituted the PUFA in the porcine AFP-PUFA complex for atractyloside and have obtained the natural effective delivery system for the powerful direct AI.

A lot of AFP conjugates were used for the targeted delivery of different toxins to cancer cells, for example, AFP-epirubicin A1 [14].

We use the non-covalent complex that is closer to natural protein form and will not provoke immune attack as AFP conjugates can possibly do. In this case we can rely on the pharmacokinetic data obtained for natural human AFP injectable drug named "Alfetin" that was shown to have 3-5 days of half-life time in the human body [15]. Pre-binding of AFP (MW=70 kDa) to atractyloside (MW=0.8 kDa) in 1:1-2 molar ratio possibly do not change pure AFP pharmacokinetic profile.

## DISCUSSION

AFP is a known oncology marker [16, 17, 18]. For the addressed delivery of the AI, we have used AFP which has highly specific receptors re-expressed on the majority of cancer cells [19] and is up taken by them [20].

AFP-mediated delivery of dioxin to cancer cells having AFP receptor (AFPR) was 200-1400 times more effective than dioxin alone [12]. The environmental toxin dioxin is itself carcinogenic [21] and is not a direct AI, so its anticancer application is problematic.

An injectable complex of AFP with an antifungal drug amphotericin B was used to treat cancer [22, 23]. Amphotericin B does not act on mitochondrion [24] and hence is not as effective as direct AI.

We non-covalently bound AFP to a proven direct AI - atractyloside which is toxic to the mitochondria (Fig. 1). The AFP-AI complex (Aimpila™) was prepared as described in [25]. Briefly, the porcine embryo blood and amniotic fluid were collected, purified and concentrated with 50 kDa MWCO ultrafiltration module, AFP was extracted by butanol, diafiltered, complexed with atractyloside in 1:1-2 molar ratios and lyophilized.

The Aimpila™ (0.02 mg in 0.2 ml of oil/day) being given orally has shown to inhibit tumor growth in the mice p388 leucosis model by 85% within 25 days and enlarged mice life survival by 36% [25].

The p388 leucosis model for Aimpila™ in mice was taken because was used before for AFP-drug conjugates testing [14].

AFP is known to be resistant to proteolytic attack from enzymes such as trypsin [26]. The oral route for peptide and protein drug delivery for several drugs was shown before [27]. The protein of the similar size as AFP - recombinant interferon- $\alpha$  is absorbed from rectal suppositories and was effective to suppress replication of the pathogenic viruses in the liver of children with hepatitis B and C [28]. The oil added to the drug formulation probably helped preventing Aimpila™ from degradation in GI tract and improved its absorption in the intestine.

An encapsulated form of Aimpila™ (0.6 mg/day) was used as monotherapy in patients with metastatic colorectal cancer (mCRC). mCRC was chosen because colon cancers have AFPR [19], and it was known to have 76,8% mutations of the p53 [3].

0.012 mg/day of the atractyloside, or 1/millionth of the pig's oral LD50=25-100 mg/kg were supposed to be non-toxic within Aimpila™ [26].

CT-scans before and after the 8 weeks of treatment has shown that 6 out of 12 mCRC patients (50%) have responded to a suboptimal dose of Aimpila™ [29]. Two (2) of these 6 patients have shown full reduction of metastasis, one (1) patient a 73% reduction of the size of his metastasis and

three (3) patients were stabilized. No significant side effects, quick growth inhibition and tumor reduction were reported in that human study. This could be attributed to the way metastases were treated by using a direct apoptosis mode of Aimpila™ action.

Breast, liver, lung, ovarian, stomach, prostate and other cancers are AFP-PR-positive [19] and could potentially be treated with Aimpila™.

The data provided here support the idea of the necessity of the right combination of specific and effective parts to form an anticancer “magic bullet”. This means a feature which inevitably induces apoptosis in cancer cells and avoids potential mutation pathways. In addition, a second feature should be added to deliver the drug only to cancer cells and internalize it for optimal results.

## CONCLUSION

Aimpila™ meets the necessary and sufficient conditions to be considered as an anticancer “magic bullet” because of its high specificity to AFP-PR-positive cancer cells and because it internalizes a tractyloside thanks to the AFP-mediated endocytosis. Moreover, it has high efficacy in killing cancer cells due to direct apoptosis inducer action.

## ACKNOWLEDGEMENTS

Help and advices of Prof. Wainson A. A., Pak N. A., Gagne S. Sharpe J. and Prof. Molchanov O. E are appreciated.

## REFERENCES

- [1] Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. *Nature* 2001; 411:342-348.
- [2] Oncology Drug Development Update – Mid-Year 2007, Updated Molecularly Targeted Agents in Development. <http://www.nmck.net/Login.aspx?ReturnUrl=%2fnewindex.aspx> (accessed February 22, 2008).
- [3] Rozan LM, El-Deiry WS. p53 downstream target genes and tumor suppression. *Cell Death and Differentiation* 2007; 14: 3-9.
- [4] Cytotoxic T cell, [http://en.wikipedia.org/wiki/Cytotoxic\\_T\\_cell](http://en.wikipedia.org/wiki/Cytotoxic_T_cell) (accessed February 25, 2008).
- [5] Putt KS, Chen GW, Pearson JM, *et al.* Small molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. *Nature Chem Biol* 2006; 2: 543-550.
- [6] Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. *Immunol Today* 1997; 18: 44-51.
- [7] Obatomi DK, Bach PH. Biochemistry and toxicology of the diterpenoid glycoside atractyloside. *Food Chem Toxicol* 1998; 36: 335-346.
- [8] Fulda S, Scaffidi C, Susin SA, *et al.* Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. *J Biol Chem* 1998; 273(51):33942-8.
- [9] Korge P, Weiss JN. Thapsigargin directly induces the mitochondrial permeability transition. *Eur J Biochem* 1999; 265: 273-280.
- [10] Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. *Eur J Cancer* 1996; 32A: 912-920.
- [11] Stewart MJ, Steenkamp V, Van der Merwe S, Zuckerman M, Crowther NJ. The cytotoxic effect of a traditional Zulu remedy, impila (Callilepis laureola). *Human Exp Toxicol* 2002; 21: 643-647.
- [12] Sotnichenko AI, Severin SE, Posypanova GA *et al.* Water-soluble 2,3,7,8-tetrachlorodibenzo-p-dioxin complex with human AFP: properties, toxicity *in vivo*, and anti-tumor activity *in vivo*. *FEBS Lett* 1999; 450: 49-51.
- [13] Torres JM, Geuskens M, Uriel J. Receptor-mediated endocytosis and recycling of AFP in human B-lymphoma and T-leukemia cells. *Int J Cancer* 1991; 47: 110-117.
- [14] Severin SE, Posypanova GA, Sotnichenko AI, *et al.* Anti-tumor activity of a covalent conjugate of the endiene antibiotic esperamicin A1 with human alpha-fetoprotein. *Dokl Akad Nauk* 1999; 366(4): 561-4.
- [15] Alfetin, <http://www.alfetin.ru/index-e.html> (accessed May 16, 2008).
- [16] Abelev GI. Alpha-fetoprotein: an insight to biology of development and to origin of tumours. *Soros Educational Magazine* 1998; 9: 8-13.
- [17] Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes and conformational variants. *Exp Biol Med* 2001; 226(5): 377-408.
- [18] Mizejewski GJ. Biological roles of alpha-fetoprotein during pregnancy and perinatal development. *Exp Biol Med* 2004; 229: 439-463.
- [19] Moro R, Tcherkassova J, Song E, *et al.* A new broad-spectrum cancer marker. *IVD Technology Magazine* 2005; June.
- [20] Laborda J, Naval J, Allouche M, Calvo M, Georgoulis V, Mishal Z, Uriel J. Specific uptake of AFP by malignant human lymphoid cells. *Int J Cancer* 1987; 40: 314-318.
- [21] Biswas G, Srinivasan S, Anandatheerthavarada HK, Avadhani NG. Dioxin-mediated tumor progression through activation of mitochondrial-to-nucleus stress signaling. *Proc Natl Acad Sci USA* 2008; 105:1: 186-191.
- [22] Pak VN, Nikonov SD, Reshetnikov SS, Pak NA, Ogirenko AP. Method of treatment of malignant neoplasm and complex preparation having antineoplastic activity for use in such treatment. US Patent 6,878,688 2005; April 12.
- [23] Pak VN, Nikonov SD, Reshetnikov SS, Pak NA, Ogirenko AP. Method of cancer treatment and a medicine for this application. Patent of Russia 2179452 2000; June 22.
- [24] Rex MC, Dawson D, Elliot C, Elliot WH, Jones KM. Data for biochemical research. Oxford Science Publications Clarendon Press Oxford Third Edition 1986; 297.
- [25] Pak V. Compositions of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer. PCT/CA2006/001867 2007; May 24. <http://www.wipo.int/pctdb/en/wo.jsp?wo=2007056852&IA=WO2007056852&DISPLAY=STATUS> (accessed February 25, 2008).
- [26] Mizejewski GJ. New insights in to AFP structure and function: potential biomedical applications. Alpha-fetoprotein and congenital disorders, Academic Press Inc 1985.
- [27] Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? *Drug Discovery Today* 2006; 11: 905-910.
- [28] Uchaikin V, Cherednichenko T, Malinovskaya V, *et al.* Use of recombinant alpha-2b-interferon in combination with antioxidants in the form of rectal suppositories (viferon) in children with chronic hepatitis B and C. *Acta Virol* 2000; 44: 79-83.
- [29] Pak V, Molchanov O, Vincent M. Treatment of metastatic colorectal cancer with aimpila, a glycoside/alpha-fetoprotein complex. *J Clin Oncol* 2007; 25: 18S: 3589.

Received: March 12, 2008

Revised: April 25, 2008

Accepted: May 20, 2008

© V. Pak; Licensee Bentham Open.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.5/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.